Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1016/j.jbi.2021.103696

http://scihub22266oqcxt.onion/10.1016/j.jbi.2021.103696
suck pdf from google scholar
33571675!7869625!33571675
unlimited free pdf from europmc33571675    free
PDF from PMC    free
html from PMC    free
PDF vom PMID33571675  :  Publisher

suck abstract from ncbi

pmid33571675
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Drug repurposing for COVID-19 via knowledge graph completion #MMPMID33571675
  • Zhang R; Hristovski D; Schutte D; Kastrin A; Fiszman M; Kilicoglu H
  • J Biomed Inform 2021[Mar]; 115 (ä): 103696 PMID33571675show ga
  • OBJECTIVE: To discover candidate drugs to repurpose for COVID-19 using literature-derived knowledge and knowledge graph completion methods. METHODS: We propose a novel, integrative, and neural network-based literature-based discovery (LBD) approach to identify drug candidates from PubMed and other COVID-19-focused research literature. Our approach relies on semantic triples extracted using SemRep (via SemMedDB). We identified an informative and accurate subset of semantic triples using filtering rules and an accuracy classifier developed on a BERT variant. We used this subset to construct a knowledge graph, and applied five state-of-the-art, neural knowledge graph completion algorithms (i.e., TransE, RotatE, DistMult, ComplEx, and STELP) to predict drug repurposing candidates. The models were trained and assessed using a time slicing approach and the predicted drugs were compared with a list of drugs reported in the literature and evaluated in clinical trials. These models were complemented by a discovery pattern-based approach. RESULTS: Accuracy classifier based on PubMedBERT achieved the best performance (F1 = 0.854) in identifying accurate semantic predications. Among five knowledge graph completion models, TransE outperformed others (MR = 0.923, Hits@1 = 0.417). Some known drugs linked to COVID-19 in the literature were identified, as well as others that have not yet been studied. Discovery patterns enabled identification of additional candidate drugs and generation of plausible hypotheses regarding the links between the candidate drugs and COVID-19. Among them, five highly ranked and novel drugs (i.e., paclitaxel, SB 203580, alpha 2-antiplasmin, metoclopramide, and oxymatrine) and the mechanistic explanations for their potential use are further discussed. CONCLUSION: We showed that a LBD approach can be feasible not only for discovering drug candidates for COVID-19, but also for generating mechanistic explanations. Our approach can be generalized to other diseases as well as to other clinical questions. Source code and data are available at https://github.com/kilicogluh/lbd-covid.
  • |*Drug Repositioning[MESH]
  • |*Knowledge Discovery[MESH]
  • |Algorithms[MESH]
  • |Antiviral Agents/therapeutic use[MESH]
  • |COVID-19/*drug therapy/virology[MESH]
  • |Humans[MESH]
  • |Neural Networks, Computer[MESH]
  • |SARS-CoV-2/isolation & purification[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    103696 ä.115 2021